Catalyst Biosciences Inc (CBIO)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nassim Usman
Employees:
21
260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA 94080
6507450655

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on creating and developing novel medicines to address serious medical conditions for patients who need new or better treatment options. The company was founded on August 5, 2002 and is headquartered in South San Francisco, CA.

Data derived from most recent annual or quarterly report
Market Cap 47.429 Million Shares Outstanding31.41 Million Avg 30-day Volume 2.288 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.8
Price to Revenue3.117 Debt to Equity0.0 EBITDA-79.799 Million
Price to Book Value0.7671 Operating Margin-1202.6557 Enterprise Value-14.042 Million
Current Ratio2.783 EPS Growth0.262 Quick Ratio2.682
1 Yr BETA 1.7063 52-week High/Low 5.2 / 0.35 Profit Margin-1200.7652
Operating Cash Flow Growth4.2418 Altman Z-Score-19.2606 Free Cash Flow to Firm -51.288 Million
Earnings Report2022-08-04
View SEC Filings from CBIO instead.

View recent insider trading info

Funds Holding CBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-09:
    Item 8.01: Other Events
  • 8-K/A: filed on 2022-05-24:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-16:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-25:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MILLER SELINE E. SVP FINANCE; INTERIM CFO & PAO

    • Officer
    107,500 2022-02-11 3

    BLOUSE GRANT E. CHIEF SCIENTIFIC OFFICER

    • Officer
    200,000 2022-02-11 4

    USMAN NASSIM PRESIDENT & CEO

    • Officer
    • Director
    30,915 2022-02-09 2

    HUNT ANDREA

    • Director
    28,228 2022-01-07 2

    WILLIAMS EDDIE

    • Director
    34,804 2022-01-07 2

    LING GEOFFREY M.D.

    • Director
    31,790 2022-01-07 2

    DESOUZA ERROL B

    • Director
    29,801 2021-10-01 1

    LAWLOR AUGUSTINE

    • Director
    48,788 2021-10-01 1

    JEW JEANNE Y

    • Director
    0 2021-09-09 2

    LEVY HOWARD CHIEF MEDICAL OFFICER

    • Officer
    24,029 2021-08-09 1

    TETLOW SHARON

    • Director
    14,000 2021-06-09 0

    MUSIL CLINTON CHIEF FINANCIAL OFFICER

    • Officer
    54,000 2021-02-08 0

    RICHARD JOHN P

    • Director
    3,716 2020-03-13 0

    CAI VERONICA CONTROLLER

    • Officer
    7,353 2020-03-13 0

    PAYNE FLETCHER CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2019-08-30 0

    HILL STEPHEN A

    • Director
    1,190 2018-09-06 0

    JFL CAPITAL MANAGEMENT, LLC

    • 5% OWNER
    0 2018-07-27 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD PARTNERS, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    5,661,484 2018-03-06 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    1,113,222 2018-03-06 0

    SELICK HAROLD E

    • Director
    0 2018-01-16 0

    MADISON EDWIN CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2015-10-22 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INC/IL

    LAMPERT MARK N

    BVF INVESTMENTS LLC

    INVESTMENT 10 LLC

    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    No longer subject to file 2015-08-20 0

    HIMAWAN JEFF

    • Director
    0 2015-08-20 0

    ESSEX WOODLANDS HEALTH VENTURES VIII, L.L.C.

    ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.

    • 10% Owner
    1,179,352 2015-08-20 0

    BROWN JULIA R

    • Director
    No longer subject to file 2015-08-14 0

    BLIXT CHARLES A

    • Director
    No longer subject to file 2015-08-14 0

    DUNTON ALAN W

    • Director
    No longer subject to file 2015-08-14 0

    HODGES MAURI K TREASURER, CFO

    • Officer
    No longer subject to file 2015-08-14 0

    ROCK PATRICK C. SECRETARY, GC

    • Officer
    No longer subject to file 2015-08-14 0

    MUSSO ALAN A SVP, FIN+ADMIN, CFO & TREAS

    • Officer
    57,799 2014-10-17 0

    TOLER STEVEN M. VP, CLIN PHARM SCIENCES

    • Officer
    46,000 2014-10-17 0

    HOSFORD DAVID A. VP, CLIN DEV & REG AFFAIRS

    • Officer
    0 2014-01-23 0

    BARRIS PETER J

    • 10% Owner
    4,563,512 2013-12-05 0

    SANDELL SCOTT D

    • 10% Owner
    4,563,512 2013-12-05 0

    BARRETT M JAMES

    • 10% Owner
    4,563,512 2013-12-03 0

    SKALETSKY MARK B

    • Director
    0 2013-06-07 0

    BENCHERIF MEROUANE SVP AND SENIOR SCIEN FELLOW

    • Officer
    0 2013-01-17 0

    BRENNAN JEFFREY P SVP, BUS. AND COMM. DEV. & CBO

    • Officer
    0 2013-01-17 0

    ZORN PETER A SVP, LGL AFFRS, GC & SECRETARY

    • Officer
    0 2013-01-17 0

    HICKS KAREN A VP, HUMAN RESOURCES

    • Officer
    0 2013-01-17 0

    INVESTMENT 10 LLC

    • SEE EXPLANATION OF RESPONSES
    6,171,669 2013-01-01 0

    KRAMLICH C RICHARD

    • 10% Owner
    4,568,845 2012-11-19 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INC/IL

    LAMPERT MARK N

    BVF INVESTMENTS LLC

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSES
    8,616,634 2012-11-14 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    5,710,899 2012-11-07 0

    BURRILL STEVEN

    • Director
    4,333 2012-07-31 0

    SNYDERMAN RALPH

    • Director
    0 2012-06-07 0

    DEBETHIZY J DONALD PRESIDENT AND CEO

    • Officer
    • Director
    0 2012-05-04 0

    CALDWELL WILLIAM S SVP - DRUG DISCOVERY AND DEV.

    • Officer
    9,235 2011-09-20 0

    DUNBAR GEOFFREY C SVP, CLIN. DEV. & REG. AFFAIRS

    • Officer
    0 2011-03-29 0

    NOMURA INTERNATIONAL PLC

    NOMURA PHASE4 VENTURES GP LTD

    NOMURA PHASE4 VENTURES LP

    NOMURA PHASE4 VENTURES LTD

    • 10% Owner
    • MEMBER OF 13G GROUPMEMBER OF 13G GROUPMEMBER OF 13G GROUP
    3,083,332 2008-04-18 0

    NEWHALL CHARLES W III

    • 10% Owner
    4,565,512 2008-01-17 0

    PERRY MARK W

    • 10% Owner
    4,565,512 2008-01-17 0

    NEW ENTERPRISE ASSOCIATES 10 L P

    • 10% Owner
    4,563,512 2008-01-17 0

    TRAINOR III EUGENE A

    • 10% Owner
    4,563,512 2008-01-17 0

    NEA PARTNERS 10 L P

    • 10% Owner
    4,563,512 2008-01-17 0

    JONES ELAINE V

    • FORMER DIRECTOR AS OF 6/13/07
    No longer subject to file 2007-11-29 0

    MORRIS PETER

    • 10% Owner
    3,264,512 2006-04-18 0

    HANHAM ANN

    • Director
    779,062 2006-04-18 0

    EUCLIDSR PARTNERS, L.P.

    EUCLIDSR ASSOCIATES, L.P.

    • 10% Owner
    1,510,080 2006-04-18 0

    EUCLIDSR BIOTECHNOLOGY ASSOCIATES, L.P.

    EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.

    • 10% Owner
    371,748 2006-04-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 22:15:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 21:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 21:15:04 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 20:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 20:15:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 19:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 19:15:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 18:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 18:15:04 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 17:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 17:15:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 16:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 16:15:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 15:45:03 UTC -9.4897 11.0597 650000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 15:15:03 UTC -9.4897 11.0597 600000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 14:45:03 UTC -9.1525 10.7225 600000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 14:15:03 UTC -9.1525 10.7225 600000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 13:45:03 UTC -9.1525 10.7225 600000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 13:15:03 UTC -9.1525 10.7225 600000
    CATALYST BIOSCIENCES INC CBIO 2022-06-24 12:45:03 UTC -9.1525 10.7225 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CBIO -100.0 shares, $-66.0 2022-03-31 N-PORT

    Elevate your investments